Cleerly and Cenegenics Partner to Offer Heart Disease Prevention Technology as Part of Performance Health Age Management Portfolio
Cenegenics’ U.S. locations now offering Cleerly’s AI-enabled approach to personalized heart care
Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.
Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.
Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.
For any questions, please reach out to press@cleerlyhealth.com
Cenegenics’ U.S. locations now offering Cleerly’s AI-enabled approach to personalized heart care
L.A. area cardiologists leverage AI-enabled approach to develop personalized heart care diagnoses and treatment plans Denver – May 3, 2023 --...
Krissy Wright joins as CFO and Sandra Statz as EVP of Regulatory Affairs to Support Company’s Mission to Create a World Without Heart Attacks New...
Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCC Research shows accuracy and effectiveness of Cleerly’s personalized...